240 results on '"Iams, Wade T."'
Search Results
2. Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast
3. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
4. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
5. Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules
6. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
7. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
8. Pragmaticism in Cancer Clinical Trials
9. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non–Small-cell Lung Cancer With Different Prognostic Significance
10. Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
11. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort
12. Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report
13. 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
14. 594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+tumors treated with cell-based vaccine, SQZ-PBMC-HPV
15. 692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
16. 595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
17. Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer
18. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes
19. Immunotherapeutic approaches for small-cell lung cancer
20. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse
21. Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
22. Data from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
23. Fig S5 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
24. TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
25. Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
26. Abstract 5606: Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer during systemic therapy
27. Abstract 3366: A machine learning approach to determine the cellular origin of variants in liquid biopsies
28. Supplementary Table S2 from Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
29. Data from Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
30. Supplementary Data from Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
31. Peripheral T-cell receptor repertoire dynamics in small cell lung cancer
32. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy
33. Carcinoid tumors outside the abdomen
34. Author Reply: In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
35. Evaluating the Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in patients with Non-Small Cell Lung Cancer (NSCLC)
36. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer
37. Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer
38. Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
39. Carcinoid tumors outside the abdomen.
40. Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN)
41. Abstract 3375: Molecular subtyping of circulating tumor cells in patients with small cell lung cancer
42. De Novo KRAS G12C–Mutant SCLC: A Case Report
43. Novel Targeted Therapies for Metastatic Melanoma
44. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
45. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
46. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
47. Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
48. Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes
49. PP01.34 Next Generation Sequencing Evaluation to Detect Circulating Tumor DNA and Minimal Residual Disease in Limited Stage Small Cell Lung Cancer
50. Abstract 5526: Serum proteomic scores for understanding response and mechanisms of resistance to immune checkpoint inhibitors in non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.